Harmony Biosciences Holdings, Inc. (HRMY) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$31.42
Price Target
$46.80
Target Range
$31.00 — $62.00
Analyst Rating
Buy
Forward P/E9.0x
Trailing P/E11.6x
Forward PEG—
Implied Growth+29.8%
Median Target$46.00
Analyst Spread66.2%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$31
-1.3%
Consensus
$47
+48.9%
Bull Case
$62
+97.3%
HRMY Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Harmony Biosciences Holdings, Inc. (HRMY) has a Wall Street consensus price target of $46.80, based on estimates from 13 covering analysts. With the stock currently trading at $31.42, this represents a potential upside of +48.9%. The company has a market capitalization of $1.82B.
Analyst price targets range from a low of $31.00 to a high of $62.00, representing a 66% spread in expectations. The median target of $46.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 10 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 2 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, HRMY trades at a trailing P/E of 11.6x and forward P/E of 9.0x. Analysts expect EPS to grow +29.8% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+41.0%
Avg Forward P/E23.4x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 JAZZJazz Pharmaceuticals plc | $14.2B | $226.96 | $216.14 | -4.8% | Buy | 9.4x | 48 |
 AVPTAvePoint, Inc. | $2.2B | $10.32 | $17.50 | +69.6% | Buy | 27.7x | 12 |
 AXSMAxsome Therapeutics, Inc. | $11.3B | $220.10 | $225.86 | +2.6% | Buy | — | 25 |
 INVAInnoviva, Inc. | $1.9B | $22.80 | $37.67 | +65.2% | Buy | 11.9x | 10 |
 SUPNSupernus Pharmaceuticals, Inc. | $3.0B | $52.28 | $60.00 | +14.8% | Buy | 24.1x | 14 |
 NKTRNektar Therapeutics | $1.7B | $83.37 | $132.83 | +59.3% | Buy | — | 33 |
 PTCTPTC Therapeutics, Inc. | $5.3B | $64.49 | $89.67 | +39.0% | Buy | — | 26 |
 RAREUltragenyx Pharmaceutical Inc. | $2.6B | $26.13 | $51.50 | +97.1% | Buy | — | 33 |
 ACADACADIA Pharmaceuticals Inc. | $3.9B | $22.57 | $34.78 | +54.1% | Buy | 50.9x | 37 |
 CRLCharles River Laboratories International, Inc. | $9.0B | $181.94 | $205.43 | +12.9% | Buy | 16.4x | 36 |
Upside Potential Comparison
RAREAVPTINVANKTRACADPTCTSUPNCRLSee HRMY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HRMY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HRMY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHRMY — Frequently Asked Questions
Quick answers to the most common questions about buying HRMY stock.
What is the HRMY stock price target for 2026?
The consensus Wall Street price target for HRMY is $46.8, representing 48.9% upside from the current price of $31.42. With 13 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is HRMY a buy, sell, or hold?
HRMY has a consensus rating of "Buy" based on 13 Wall Street analysts. The rating breakdown is predominantly bullish, with 10 Buy/Strong Buy ratings. The consensus 12-month price target of $46.8 implies 48.9% upside from current levels.
Is HRMY stock overvalued or undervalued?
With a forward P/E of 8.9541x, HRMY trades at a relatively low valuation. The consensus target of $46.8 implies 48.9% appreciation, suggesting meaningful undervaluation.
How high can HRMY stock go?
The most bullish Wall Street analyst has a price target of $62 for HRMY, while the most conservative target is $31. The consensus of $46.8 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover HRMY stock?
HRMY is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 10 have Buy ratings, 1 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the HRMY stock forecast?
The 12-month HRMY stock forecast based on 13 Wall Street analysts shows a consensus price target of $46.8, with estimates ranging from $31 (bear case) to $62 (bull case). The median consensus rating is "Buy".
What is HRMY's forward P/E ratio?
HRMY trades at a forward P/E ratio of 9.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 11.6x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy HRMY stock?
Wall Street analysts are very optimistic on HRMY, with a "Buy" consensus rating and $46.8 price target (48.9% upside). 10 of 13 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do HRMY price targets vary so much?
HRMY analyst price targets range from $31 to $62, a 66% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $46.8 consensus represents the middle ground.